Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study
NCT07297602
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
36
Enrollment
OTHER
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Oral roflumilast
Sponsor
Nora Mohamed Abdelrazik
Collaborators
[object Object]